Fig. 3: ZHX2 targeted and negatively regulated linc00707.

A Expression levels of linc00707 in glioma tissues. Data are presented as the mean ± SD (n = 9, each group). *P < 0.05, **P < 0.01 vs. NBTs group; #P < 0.05 vs. LGGTs group. B Expression levels of linc00707 in glioma cells. Data are presented as the mean ± SD (n = 3, each group). *P < 0.05, **P < 0.01 vs. HA group. C–E CCK-8 assay, transwell, and three-dimensional culture were applied to evaluate the proliferation, migration, invasion, and tube formation effect of linc00707 on U87 and U251 cells. Representative images and corresponding statistical plots are shown. The scale bar represents 50 µm. F Protein levels of MMP2, MMP9, and VE-cadherin regulated by linc00707 in U87 and U251 cells. Data are presented as the mean ± SD (n = 3, each group). *P < 0.05,**P < 0.01 vs. linc00707(−)-NC group. G Schematic representation of linc00707 promoter region in 3000 bp upstream of the transcription start site (TSS; designated as +1). PCR products for putative linc00707 binding sites and an upstream region not expected to associate with ZHX2 were depicted with bold lines. Dashed lines represent the primers used for each PCR. The image was representative of independent ChIP experiments. H Expression levels of linc00707 regulated by ZHX2 in U87 and U251 cells. Data are presented as the mean ± SD (n = 3, each group). *P < 0.05, **P < 0.01 vs. ZHX2(+)-NC group. I RT-qPCR analysis for HNRNPD and ZHX2 regulating linc00707 expression in U87 and U251 cells. Data are presented as the mean ± SD (n = 3, each group). *P < 0.05, **P < 0.01 vs. HNRNPD(−)-NC + ZHX2(+)-NC group; #P < 0.05 vs. HNRNPD(−) + ZHX2(+)-NC group; &P < 0.05 vs. HNRNPD(−)-NC + ZHX2(+) group.